- Home
- LGMK vs ATXI Comparison
LGMK vs ATXI Comparison
Compare LGMK & ATXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGMK
- ATXI
- Stock Information
- Founded
- LGMK 2011
- ATXI 2015
- Country
- LGMK United States
- ATXI United States
- Employees
- LGMK N/A
- ATXI N/A
- Industry
- LGMK Industrial Specialties
- ATXI Biotechnology: Pharmaceutical Preparations
- Sector
- LGMK Health Care
- ATXI Health Care
- Exchange
- LGMK Nasdaq
- ATXI Nasdaq
- Market Cap
- LGMK 3.5M
- ATXI 3.0M
- IPO Year
- LGMK N/A
- ATXI 2017
- Fundamental
- Price
- LGMK $1.41
- ATXI $1.85
- Analyst Decision
- LGMK
- ATXI
- Analyst Count
- LGMK 0
- ATXI 0
- Target Price
- LGMK N/A
- ATXI N/A
- AVG Volume (30 Days)
- LGMK 304.5K
- ATXI 61.4K
- Earning Date
- LGMK 11-12-2024
- ATXI 11-14-2024
- Dividend Yield
- LGMK N/A
- ATXI N/A
- EPS Growth
- LGMK N/A
- ATXI N/A
- EPS
- LGMK N/A
- ATXI N/A
- Revenue
- LGMK $10,078,502.00
- ATXI N/A
- Revenue This Year
- LGMK $1.54
- ATXI N/A
- Revenue Next Year
- LGMK N/A
- ATXI N/A
- P/E Ratio
- LGMK N/A
- ATXI N/A
- Revenue Growth
- LGMK 4.44
- ATXI N/A
- 52 Week Low
- LGMK $1.32
- ATXI $1.60
- 52 Week High
- LGMK $32.25
- ATXI $15.00
- Technical
- Relative Strength Index (RSI)
- LGMK 38.44
- ATXI 47.67
- Support Level
- LGMK $1.32
- ATXI $1.72
- Resistance Level
- LGMK $1.49
- ATXI $2.04
- Average True Range (ATR)
- LGMK 0.15
- ATXI 0.19
- MACD
- LGMK 0.01
- ATXI -0.00
- Stochastic Oscillator
- LGMK 20.79
- ATXI 33.39
About LGMK LogicMark Inc. (NV)
LogicMark Inc provides personal emergency response systems (PERS), health communications devices, and IoT technologies to create a connected care platform. Its devices give people the ability to receive care at home and confidence to age in place. The company incorporates two-way voice communication technology directly into its medical alert pendant and provides this life-saving technology at a price point that everyday consumers can afford.
About ATXI Avenue Therapeutics Inc.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.